上海醫藥(02607.HK):非公開發行新增A股股份約8.53億股
格隆匯4月11日丨上海醫藥(02607.HK)公吿,2021年度非公開發行A股股票發行結果,公司發行新增852,626,796股份已於2022年4月8日在中國證券登記結算有限責任公司上海分公司辦理完畢股份登記手續。本次發行新增股份為有限售條件流通股,將於限售期屆滿後的次一交易日起在上海證券交易所上市流通交易,如遇法定節假日或休息日,則順延至其後的第一個交易日。
本次非公開發行股票完成後,上海潭東企業諮詢服務有限公司(以下簡稱“上海潭東”)和雲南白藥集團股份有限公司(以下簡稱“雲南白藥”)本次認購獲得的公司新發行股份,自本次非公開發行結束日起36個月內不得轉讓。本次發行結束後,上述發行對象所認購的公司股份因送股、資本公積金轉增股本等情形所衍生取得的股份亦應遵守上述股份限售安排。本次發行的募集資金淨額為人民幣139.3億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.